503B Outsourcing

A Smarter Approach to Medication Access

Health systems are under constant pressure to maintain a reliable supply of safe, ready-to-use medications — especially during shortages or periods of operational strain. 503B outsourcing facilities play a critical role in supporting that need.

As FDA-registered outsourcing facilities, 503B providers can compound sterile medications in advance — without patient-specific prescriptions — while adhering to strict current Good Manufacturing Practice (cGMP) standards. This enables hospitals to reduce dependence on in-house compounding while gaining greater consistency, scalability, and regulatory assurance.

At Olyx Pharma, 503B outsourcing is more than a supply solution — it's a strategic extension of your pharmacy operations. We help health systems strengthen medication availability, improve workflow efficiency, and make confident decisions even in uncertain supply environments.

cGMP
Compliant

Extending Your Capabilities

What 503B Outsourcing Does for Your Pharmacy

Reduce Operational Burden

p>Shift complex sterile compounding outside the hospital to free up staff time and internal resources for higher-value clinical work.

Lower Compliance Risk

Minimize exposure to evolving regulatory requirements tied to in-house sterile compounding.

Optimize Capital Allocation

Avoid significant investments in cleanrooms, equipment, and ongoing validation required for in-house sterile compounding.

Improve Workflow Efficiency

Access ready-to-administer formats such as syringes, IV bags, and ambulatory pump (CADD) solutions.

Focus on Patient Care

Enable pharmacy teams to prioritize clinical responsibilities, safety initiatives, and patient outcomes.

Proactive Supply Planning

503B outsourcing provides a dependable pathway to maintain continuity of care by combining quality manufacturing with forward-looking supply planning.

What 503B Outsourcing Means for Health Systems